Carboplatin – Uses, Dosage, Side Effects, Interaction Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxylic residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04) Carboplatin is an intravenously administered platinum coordination complex and alkylating agent which is used as a chemotherapeutic agent for the treatment of various cancers, mainly ovarian, head and neck, and lung cancers. Carboplatin therapy is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent liver injury. Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting. Carboplatin was granted FDA approval on 3 March 1989. Mechanism of Action Carboplatin predominantly acts by attaching alkyl groups to the nucleotides, leading to the formation of mono adducts, and DNA fragmenting when repair enzymes attempt to correct the error. 2% of carboplatin’s activity comes from DNA cross-linking from a base on one strand to a base on another, preventing DNA strands from separating for synthesis or transcription. Finally, carboplatin can induce a number of different mutations. Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Carboplatin has a long duration of action as it is given every 4 weeks and has a narrow therapeutic index. Patients should be counseled regarding bone marrow suppression and anemia. Indications Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy. Carboplatin is an intravenously administered platinum coordination complex and alkylating agent which is used as a chemotherapeutic agent for the treatment of various cancers, mainly ovarian, head and neck, and lung cancers. Carboplatin therapy is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent liver injury. Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[rx] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy. Advanced Cervical Cancer Advanced Endometrial Cancer Advanced Esophageal Cancers Advanced Head and Neck Cancer Advanced Melanoma Advanced Non-Small Cell Lung Cancer (NSCLC) Advanced Ovarian Carcinoma Advanced Sarcoma Malignant Pleural Mesothelioma (MPM) Merkel Cell Carcinoma Metastatic Breast Cancer Refractory Hodgkin Lymphoma Retinoblastoma Advanced Bladder cancer Advanced Small cell lung Conditioning regimens for allogeneic stem cell transplantation therapy Use in Cancer Carboplatin is approved to be used alone or with other drugs to treat: Ovarian cancer is advanced. It is used with other chemotherapy as a first-line treatment. It is used alone as palliative treatment for the disease that has recurred (come back) after earlier chemotherapy. Carboplatin is also being studied in the treatment of other types of cancer. Contraindications are sensitive or allergic to carboplatin or any ingredients of the medication are sensitive or allergic to platinum-containing compounds have severely reduced bone marrow function have severely reduced kidney function Hypersensitivity to the active component, any of the ingredients, or platinum-containing compounds Additional and/or more frequent monitoring should be done to ensure receipt of an effective dose while avoiding unnecessary toxicities Severe bone marrow depression Severe bleeding a bad infection decreased function of bone marrow anemia an increased risk of bleeding decreased blood platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils a painful condition that affects the nerves in the legs and arms called peripheral neuropathy hearing loss bleeding liver problems decreased kidney function excessive vomiting abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding Dosages Strengths: 10 mg/mL; 50 mg; 150 mg; 450 mg Ovarian Cancer SINGLE AGENT THERAPY for use in the treatment of recurrent ovarian cancer: 360 mg/m2 by IV on day 1 every 4 weeks (alternatively, the carboplatin dose may be calculated by the Calvert formula below). Usually, single intermittent courses should not be repeated until the neutrophil count is at least 2000 and the platelet count is at least 100,000. COMBINATION THERAPY (with cyclophosphamide) for use in the treatment of advanced ovarian cancer (an effective combination for previously untreated patients): Carboplatin: 300 mg/m2 by IV on day 1 every 4 weeks for 6 cycles (alternatively, the carboplatin dose may be calculated by the Calvert formula below) Cyclophosphamide 600 mg/m2 IV on day 1 every 4 weeks for 6 cycles Intermittent courses of carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2000 and the platelet count is at least 100,000. FORMULA DOSING: Another way to determine the initial dose is the use of a mathematical formula based on a patient’s preexisting renal function or renal function and desired platelet nadir (renal excretion is the major route of elimination for this drug). The use of this formula allows compensation for patient variations in pretreatment renal function that might otherwise result in either under-dosing (in patients with above-average renal function) or overdosing (in patients with impaired renal function). CALVERT FORMULA: Total Dose (mg) = (target AUC) x (GFR + 25); Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m2 This drug is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required. The target AUC of 4 to 6 mg/mL/min using single-agent carboplatin appears to provide the most appropriate dose range in previously treated patients. To avoid potential toxicity due to overdosing, if a patient’s GFR is estimated based on serum creatinine measured by the standardized Isotope Dilution Mass Spectrometry (IDMS) method rather than using an actual GFR measurement, a capping of the dose of carboplatin for the desired exposure (AUC) has been recommended. For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. For the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Renal Dose Adjustments Patients with Impaired Kidney Function: Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single-agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used. CrCl 41 to 59 mL/min: The recommended dose on Day 1 is 250 mg/m2 CrCl 16 to 40 mL/min: The recommended dose on Day 1 is 200 mg/m2 CrCl less than 15 mL/min: Data not available Dose Adjustments Pretreatment platelet count and performance status are important prognostic factors for the severity of myelosuppression in previously treated patients. The suggested dose adjustments for single agent or combination therapy shown below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value: Platelets greater than 100,000 and neutrophils greater than 2000: Adjust dose from prior course to 125% Platelets 50,000 to 100,000 and neutrophils 500 to 2000: No adjustment Platelets less than 50,000: adjust dose from prior course to 75% NOTE: Percentages apply to carboplatin as a single agent or to both carboplatin and cyclophosphamide in combination. In studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended. Side Effects The Most Common nausea vomiting diarrhea constipation black, tarry, or bloody stools bloody vomit or vomited material that looks like coffee grounds unusual bruising or bleeding decreased urination pain, burning, or tingling in the hands or feet ringing in ears and difficulty hearing sores in the mouth and throat pain, burning, or tingling in the hands or feet pain, itching, redness, swelling, blisters, or sores in the place where the medication was injected hair loss pain weakness loss in ability to taste food pale skin unusual tiredness or weakness fainting dizziness sudden changes in vision, including color vision decreased urination swelling of the face, arms, hands, feet, ankles, or lower legs shortness of breath with everyday activity or when lying flat ringing in ears and difficulty hearing More Common low magnesium–dizziness, irregular heartbeats, feeling jittery, muscle cramps, muscle spasms, cough or choking feeling. bleeding and reduced blood cells, including reduced red blood cells (anemia) and platelets (needed for proper blood clotting), which may be severe enough to require a blood transfusion. You should tell your doctor right away if you notice any unusual bruising or bleeding, including black tarry stools or blood in the urine. infection – carboplatin can temporarily lower the number of white blood cells in your blood, increasing the risk of infection; life-threatening allergic reaction – during and after treatment the doctor or nurse will observe you carefully for signs of allergic reaction; kidney and liver problems; loss of hearing or ringing in the ears; Rare bleeding unusual bruising or bleeding, black tarry stools, or blood in the urine; infection; life-threatening allergic reaction; kidney and liver problems; or loss of hearing or ringing in the ears. low blood cell counts; nausea, vomiting; abnormal liver function tests; low magnesium; temporary hair loss; or pain or weakness signs of bleeding (e.g., bloody, black, or tarry stools, vomiting blood or material that looks like coffee grounds, blood in the urine, unusual bruising or bleeding, cuts that won’t stop bleeding, nosebleeds) signs of kidney problems (e.g., increased urination at night, decreased urine production, blood in the urine, change of urine color) skin rash or itching signs of a skin reaction at the injection site (e.g., red streaks along the vein where medication was injected, pain at the injection site, redness, or warmth at the site of injection) signs of infection (e.g., fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness, cough, or hoarseness) symptoms of vaso-occlusive disease (e.g., fluid buildup in the abdomen, swelling, yellowing of the skin or eyes, rapid weight gain) Drug Interaction DRUG INTERACTION Abacavir Carboplatin may decrease the excretion rate of Abacavir which could result in a higher serum level. Abatacept The risk or severity of adverse effects can be increased when Carboplatin is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Carboplatin. Aceclofenac The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Aceclofenac. Acemetacin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Carboplatin. Acetaminophen Carboplatin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Carboplatin. Aclidinium Carboplatin may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Carboplatin may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Carboplatin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Carboplatin. Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Carboplatin. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Carboplatin. Albutrepenonacog alfa Carboplatin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Alclofenac. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carboplatin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Carboplatin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin. Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Alendronic acid. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Carboplatin. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Carboplatin. Almasilate Carboplatin may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Carboplatin may decrease the excretion rate of Almotriptan which could result in a higher serum level. Alogliptin Carboplatin may decrease the excretion rate of Alogliptin which could result in a higher serum level. Alprazolam Carboplatin may decrease the excretion rate of Alprazolam which could result in a higher serum level. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Carboplatin. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Carboplatin. Amantadine Carboplatin may decrease the excretion rate of Amantadine which could result in a higher serum level. Amikacin The risk or severity of ototoxicity and nephrotoxicity can be increased when Amikacin is combined with Carboplatin. Amiloride Amiloride may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Aminophenazone The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Aminophenazone. Amitriptyline Carboplatin may decrease the excretion rate of Amitriptyline which could result in a higher serum level. Ammonium chloride Carboplatin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amoxicillin Carboplatin may decrease the excretion rate of Amoxicillin which could result in a higher serum level. Amphetamine Carboplatin may decrease the excretion rate of Amphetamine which could result in a higher serum level. Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Carboplatin. Ampicillin Carboplatin may decrease the excretion rate of Ampicillin which could result in a higher serum level. Amrinone Carboplatin may decrease the excretion rate of Amrinone which could result in a higher serum level. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Carboplatin. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Carboplatin. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Carboplatin. Ancestim Carboplatin may decrease the excretion rate of Ancestim which could result in a higher serum level. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Carboplatin. Anifrolumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Carboplatin. Anthrax The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carboplatin. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Carboplatin. Antihemophilic Carboplatin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. Antilymphocyte The risk or severity of adverse effects can be increased when Carboplatin is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Antipyrine. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carboplatin. Antithrombin III human Carboplatin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin. Antrafenine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Antrafenine. Apalutamide Carboplatin may decrease the excretion rate of Apalutamide which could result in a higher serum level. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Carboplatin. Apremilast The risk or severity of adverse effects can be increased when Carboplatin is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Carboplatin. Arformoterol Carboplatin may decrease the excretion rate of Arformoterol which could result in a higher serum level. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Carboplatin. Arsenic trioxide The risk or severity of adverse effects can be increased when Carboplatin is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Articaine. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Carboplatin. Atazanavir The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Atazanavir. Atomoxetine Carboplatin may decrease the excretion rate of Atomoxetine which could result in a higher serum level. Auranofin Carboplatin may decrease the excretion rate of Auranofin which could result in a higher serum level. Aurothioglucose Carboplatin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Carboplatin. Azathioprine The risk or severity of adverse effects can be increased when Carboplatin is combined with Azathioprine. Azelaic acid Carboplatin may decrease the excretion rate of Azelaic acid which could result in a higher serum level. Aztreonam Carboplatin may decrease the excretion rate of Aztreonam which could result in a higher serum level. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Carboplatin. Bacillus antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Carboplatin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Carboplatin. Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Carboplatin. Baclofen Carboplatin may decrease the excretion rate of Baclofen which could result in a higher serum level. Balsalazide The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Balsalazide. Baricitinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Carboplatin. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Carboplatin. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Carboplatin. Belatacept The risk or severity of adverse effects can be increased when Carboplatin is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Carboplatin is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Carboplatin is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Carboplatin. Bendamustine The risk or severity of adverse effects can be increased when Carboplatin is combined with Bendamustine. Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Benorilate The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Benorilate. Benoxaprofen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Benoxaprofen. Benserazide Carboplatin may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine Carboplatin may decrease the excretion rate of Benzatropine which could result in a higher serum level. Benznidazole Carboplatin may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Benzocaine. Benzthiazide Benzthiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Benzydamine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Benzyl alcohol. Bepotastine Carboplatin may decrease the excretion rate of Bepotastine which could result in a higher serum level. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Carboplatin. Bexarotene The serum concentration of Bexarotene can be increased when it is combined with Carboplatin. Bicisate Carboplatin may decrease the excretion rate of Bicisate which could result in a higher serum level. Bimekizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Bimekizumab. Bismuth subgallate Carboplatin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bisoprolol Carboplatin may decrease the excretion rate of Bisoprolol which could result in a higher serum level. Bisoxatin Carboplatin may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Carboplatin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Carboplatin. Blinatumomab The risk or severity of adverse effects can be increased when Carboplatin is combined with Blinatumomab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Carboplatin. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Carboplatin. Bosutinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Carboplatin is combined with Brentuximab vedotin. Brivaracetam Carboplatin may decrease the excretion rate of Brivaracetam which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Brodalumab. Bromazepam Carboplatin may decrease the excretion rate of Bromazepam which could result in a higher serum level. Bromotheophylline Bromotheophylline may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Budesonide The risk or severity of adverse effects can be increased when Carboplatin is combined with Budesonide. Bumadizone The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Bumadizone. Bumetanide The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Carboplatin. Bupivacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Bupivacaine. Bupropion Carboplatin may decrease the excretion rate of Bupropion which could result in a higher serum level. Buspirone Carboplatin may decrease the excretion rate of Buspirone which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Carboplatin is combined with Busulfan. Butabarbital Carboplatin may decrease the excretion rate of Butabarbital which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Carboplatin is combined with Cabazitaxel. Canagliflozin Canagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Canakinumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Carboplatin. Canrenoic acid Canrenoic acid may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Carboplatin. Capreomycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Capreomycin is combined with Carboplatin. Capsaicin The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Carboplatin. Carbidopa Carboplatin may decrease the excretion rate of Carbidopa which could result in a higher serum level. Carfilzomib The risk or severity of adverse effects can be increased when Carboplatin is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Carboplatin. Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Carboplatin. Cefaclor The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Carboplatin. Cefadroxil The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefadroxil. Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Carboplatin. Cefamandole The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefamandole. Cefapirin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefapirin. Cefazolin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefazolin. Cefdinir Carboplatin may decrease the excretion rate of Cefdinir which could result in a higher serum level. Cefditoren The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefditoren. Cefepime The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefepime. Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Carboplatin. Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Carboplatin. Cefonicid The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefonicid. Cefoperazone The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefoperazone. Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Carboplatin. Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Carboplatin. Cefotetan The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefotetan. Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Carboplatin. Cefoxitin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefoxitin. Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Carboplatin. Cefpirome The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefpirome. Cefpodoxime The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefpodoxime. Cefprozil The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefprozil. Cefradine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefradine. Ceftaroline fosamil The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftaroline fosamil. Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Carboplatin. Ceftibuten The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftibuten. Ceftizoxime The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftizoxime. Ceftobiprole The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftobiprole. Ceftolozane Carboplatin may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftriaxone. Cefuroxime The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefuroxime. Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Carboplatin. Cephalexin The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Carboplatin. Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Carboplatin. Certolizumab pegol The risk or severity of adverse effects can be increased when Carboplatin is combined with Certolizumab pegol. Cetirizine Carboplatin may decrease the excretion rate of Cetirizine which could result in a higher serum level. Cevimeline Carboplatin may decrease the excretion rate of Cevimeline which could result in a higher serum level. Chloral hydrate Carboplatin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Carboplatin. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Carboplatin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Chloroprocaine. Chloroquine Carboplatin may decrease the excretion rate of Chloroquine which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Carboplatin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpromazine Carboplatin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level. Chlorpropamide Carboplatin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. Chlorthalidone Chlorthalidone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Carboplatin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. Choline C 11 Carboplatin may decrease the excretion rate of Choline C 11 which could result in a higher serum level. Choline magnesium The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Choline magnesium trisalicylate. Choline salicylate Carboplatin may decrease the excretion rate of Choline salicylate which could result in a higher serum level. Chondroitin sulfate Carboplatin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Carboplatin may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Carboplatin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Carboplatin may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium gluconate Carboplatin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicotinate Carboplatin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. You Might Also Read Barosmin - Uses, Dosage, Side Effects Chromous sulfate Carboplatin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Ciclesonide The risk or severity of adverse effects can be increased when Carboplatin is combined with Ciclesonide. Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Carboplatin. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Carboplatin. Cimetidine Carboplatin may decrease the excretion rate of Cimetidine which could result in a higher serum level. Cinchocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Cinchocaine. Ciprofloxacin Carboplatin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Carboplatin. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Carboplatin. Clevidipine Carboplatin may decrease the excretion rate of Clevidipine which could result in a higher serum level. Clobazam Carboplatin may decrease the excretion rate of Clobazam which could result in a higher serum level. Clobetasol propionate The risk or severity of adverse effects can be increased when Carboplatin is combined with Clobetasol propionate. Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Clodronic acid. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Carboplatin. Clomipramine Carboplatin may decrease the excretion rate of Clomipramine which could result in a higher serum level. Clonazepam Carboplatin may decrease the excretion rate of Clonazepam which could result in a higher serum level. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Carboplatin. Clorazepic acid Carboplatin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carboplatin. Clove oil Carboplatin may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine The risk or severity of neutropenia can be increased when Carboplatin is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Cocaine. Colchicine Carboplatin may decrease the excretion rate of Colchicine which could result in a higher serum level. Colistimethate The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Colistimethate. Colistin The risk or severity of ototoxicity and nephrotoxicity can be increased when Colistin is combined with Carboplatin. Conivaptan Conivaptan may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Conjugated estrogens Carboplatin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Corifollitropin alfa Carboplatin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Corticotropin The risk or severity of adverse effects can be increased when Carboplatin is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Carboplatin is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carboplatin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carboplatin. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carboplatin. Cyclosporine Carboplatin may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide Cyclothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Cytarabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Carboplatin. Dabigatran etexilate Carboplatin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Carboplatin. Dactinomycin The risk or severity of adverse effects can be increased when Carboplatin is combined with Dactinomycin. Dalfampridine Carboplatin may decrease the excretion rate of Dalfampridine which could result in a higher serum level. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Carboplatin. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Carboplatin. Dapagliflozin Dapagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboplatin. Dasatinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin. Decitabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Decitabine. Deferiprone Carboplatin may decrease the excretion rate of Deferiprone which could result in a higher serum level. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Carboplatin. Deflazacort The risk or severity of adverse effects can be increased when Carboplatin is combined with Deflazacort. Delafloxacin Carboplatin may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Carboplatin. Desipramine Carboplatin may decrease the excretion rate of Desipramine which could result in a higher serum level. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Carboplatin. Desmopressin Carboplatin may decrease the excretion rate of Desmopressin which could result in a higher serum level. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Carboplatin. Desvenlafaxine Carboplatin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Deucravacitinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Deucravacitinib. Deutetrabenazine Carboplatin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. Dexamethasone The risk or severity of adverse effects can be increased when Carboplatin is combined with Dexamethasone. Dexibuprofen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Dexibuprofen. Dexketoprofen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Dexketoprofen. Dexmedetomidine Carboplatin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. Dexpanthenol Carboplatin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin. Dextran Carboplatin may decrease the excretion rate of Dextran which could result in a higher serum level. Diatrizoate Carboplatin may decrease the excretion rate of Diatrizoate which could result in a higher serum level. Diazepam Carboplatin may decrease the excretion rate of Diazepam which could result in a higher serum level. Dichlorobenzyl alcohol Carboplatin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Carboplatin. Diclofenamide Diclofenamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Carboplatin. Dicyclomine Carboplatin may decrease the excretion rate of Dicyclomine which could result in a higher serum level. Didanosine Carboplatin may decrease the excretion rate of Didanosine which could result in a higher serum level. Dienogest Carboplatin may decrease the excretion rate of Dienogest which could result in a higher serum level. Diflunisal The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Carboplatin. Difluocortolone The risk or severity of adverse effects can be increased when Carboplatin is combined with Difluocortolone. Digoxin Carboplatin may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydrostreptomycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Dihydrostreptomycin is combined with Carboplatin. Dimercaprol Carboplatin may decrease the excretion rate of Dimercaprol which could result in a higher serum level. Dimethyl fumarate The risk or severity of adverse effects can be increased when Carboplatin is combined with Dimethyl fumarate. Dimethyl sulfoxide Carboplatin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. Dinutuximab The risk or severity of adverse effects can be increased when Carboplatin is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Carboplatin. Diroximel fumarate The risk or severity of adverse effects can be increased when Carboplatin is combined with Diroximel fumarate. Disopyramide Carboplatin may decrease the excretion rate of Disopyramide which could result in a higher serum level. DL-Methylephedrine Carboplatin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Carboplatin may decrease the excretion rate of Dobutamine which could result in a higher serum level. Docetaxel The risk or severity of adverse effects can be increased when Carboplatin is combined with Docetaxel. Dopamine Carboplatin may decrease the excretion rate of Dopamine which could result in a higher serum level. Doripenem Carboplatin may decrease the excretion rate of Doripenem which could result in a higher serum level. Doxacurium Carboplatin may decrease the excretion rate of Doxacurium which could result in a higher serum level. Doxepin Carboplatin may decrease the excretion rate of Doxepin which could result in a higher serum level. Doxorubicin The risk or severity of adverse effects can be increased when Carboplatin is combined with Doxorubicin. Doxycycline Carboplatin may decrease the excretion rate of Doxycycline which could result in a higher serum level. Drospirenone Drospirenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Duloxetine Carboplatin may decrease the excretion rate of Duloxetine which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Dyclonine. Dyphylline Carboplatin may decrease the excretion rate of Dyphylline which could result in a higher serum level. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Carboplatin. Eculizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Carboplatin. Edoxaban Carboplatin may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Carboplatin may decrease the excretion rate of Edrophonium which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin. Emapalumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Emapalumab. Enalaprilat Carboplatin may decrease the excretion rate of Enalaprilat which could result in a higher serum level. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Carboplatin. Enzalutamide Carboplatin may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Carboplatin. Eplerenone Eplerenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Carboplatin. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Carboplatin. Eribulin The risk or severity of adverse effects can be increased when Carboplatin is combined with Eribulin. Ertapenem Carboplatin may decrease the excretion rate of Ertapenem which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carboplatin. Estazolam Carboplatin may decrease the excretion rate of Estazolam which could result in a higher serum level. Estradiol Carboplatin may decrease the excretion rate of Estradiol which could result in a higher serum level. Estradiol acetate Carboplatin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. Estradiol cypionate Carboplatin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. Estradiol dienanthate Carboplatin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. Estradiol valerate Carboplatin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. Estramustine The risk or severity of adverse effects can be increased when Carboplatin is combined with Estramustine. Estrone sulfate Carboplatin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. Eszopiclone Carboplatin may decrease the excretion rate of Eszopiclone which could result in a higher serum level. Etacrynic acid The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Carboplatin. Etafedrine Carboplatin may decrease the excretion rate of Etafedrine which could result in a higher serum level. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Carboplatin. Ethambutol Carboplatin may decrease the excretion rate of Ethambutol which could result in a higher serum level. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Etidocaine. Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Etidronic acid. Etodolac The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Carboplatin. Etomidate Carboplatin may decrease the excretion rate of Etomidate which could result in a higher serum level. Etonogestrel Carboplatin may decrease the excretion rate of Etonogestrel which could result in a higher serum level. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Carboplatin. Etoricoxib The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Etoricoxib. Eucalyptus oil Carboplatin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Everolimus The risk or severity of adverse effects can be increased when Carboplatin is combined with Everolimus. Ezogabine Carboplatin may decrease the excretion rate of Ezogabine which could result in a higher serum level. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Carboplatin. Fenbufen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Fenbufen. Fenofibrate Carboplatin may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fenofibric acid Carboplatin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam Carboplatin may decrease the excretion rate of Fenoldopam which could result in a higher serum level. Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Carboplatin. Fentanyl Carboplatin may decrease the excretion rate of Fentanyl which could result in a higher serum level. Fesoterodine Carboplatin may decrease the excretion rate of Fesoterodine which could result in a higher serum level. Filgotinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Filgotinib. Finerenone Finerenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Fingolimod Carboplatin may increase the immunosuppressive activities of Fingolimod. Flavoxate Carboplatin may decrease the excretion rate of Flavoxate which could result in a higher serum level. Floctafenine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Floctafenine. Florbetaben (18F) Carboplatin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir (18F) Carboplatin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Carboplatin. Fluconazole Carboplatin may decrease the excretion rate of Fluconazole which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Carboplatin is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Fludarabine. Fludeoxyglucose Carboplatin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Carboplatin. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Carboplatin. Flumazenil Carboplatin may decrease the excretion rate of Flumazenil which could result in a higher serum level. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Carboplatin. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Carboplatin. Fluocinonide The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Carboplatin. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carboplatin. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carboplatin. Fluprednisolone The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluprednisolone. Flurazepam Carboplatin may decrease the excretion rate of Flurazepam which could result in a higher serum level. Flurbiprofen The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Carboplatin. Flutamide Carboplatin may decrease the excretion rate of Flutamide which could result in a higher serum level. Fluticasone The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Carboplatin. Fluvoxamine Carboplatin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level. Folic acid Carboplatin may decrease the excretion rate of Folic acid which could result in a higher serum level. Fomepizole Carboplatin may decrease the excretion rate of Fomepizole which could result in a higher serum level. Fondaparinux Carboplatin may decrease the excretion rate of Fondaparinux which could result in a higher serum level. Formestane Carboplatin may decrease the excretion rate of Formestane which could result in a higher serum level. Foscarnet The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Foscarnet. Fosfomycin Carboplatin may decrease the excretion rate of Fosfomycin which could result in a higher serum level. Fosinopril Carboplatin may decrease the excretion rate of Fosinopril which could result in a higher serum level. Fosphenytoin Carboplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. Framycetin The risk or severity of ototoxicity and nephrotoxicity can be increased when Framycetin is combined with Carboplatin. Furosemide The risk or severity of nephrotoxicity can be increased when Furosemide is combined with Carboplatin. Gabapentin enacarbil Carboplatin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid Carboplatin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. Gadodiamide Carboplatin may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Gadofosveset trisodium Carboplatin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. Gadopentetic acid Carboplatin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. You Might Also Read Darbepoetin alfa - Uses, Dosage, Side Effects, Interactions Inositol Carboplatin may decrease the excretion rate of Inositol which could result in a higher serum level. Inotersen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Inotersen. Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carboplatin. Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carboplatin. Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carboplatin. Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carboplatin. Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin. Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin. Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carboplatin. Iobenguane sulfate I-123 Carboplatin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. Iodixanol Carboplatin may decrease the excretion rate of Iodixanol which could result in a higher serum level. Ioflupane I-123 Carboplatin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Iopromide Carboplatin may decrease the excretion rate of Iopromide which could result in a higher serum level. Iothalamic acid Carboplatin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Ioversol Carboplatin may decrease the excretion rate of Ioversol which could result in a higher serum level. Ioxilan Carboplatin may decrease the excretion rate of Ioxilan which could result in a higher serum level. Ipecac Carboplatin may decrease the excretion rate of Ipecac which could result in a higher serum level. Ipilimumab Carboplatin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Carboplatin. Isoniazid Carboplatin may decrease the excretion rate of Isoniazid which could result in a higher serum level. Isosorbide Isosorbide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Isosorbide mononitrate Carboplatin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. Isosulfan blue Carboplatin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. Isotretinoin Carboplatin may decrease the excretion rate of Isotretinoin which could result in a higher serum level. Isoxicam The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Isoxicam. Isradipine Carboplatin may decrease the excretion rate of Isradipine which could result in a higher serum level. Ixabepilone The risk or severity of adverse effects can be increased when Carboplatin is combined with Ixabepilone. Ixazomib Carboplatin may decrease the excretion rate of Ixazomib which could result in a higher serum level. Ixekizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Ixekizumab. Kanamycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Kanamycin is combined with Carboplatin. Ketamine Carboplatin may decrease the excretion rate of Ketamine which could result in a higher serum level. Ketazolam Carboplatin may decrease the excretion rate of Ketazolam which could result in a higher serum level. Ketoprofen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ketoprofen. Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Carboplatin. Labetalol Carboplatin may decrease the excretion rate of Labetalol which could result in a higher serum level. Lamivudine Carboplatin may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine Carboplatin may decrease the excretion rate of Lamotrigine which could result in a higher serum level. Latamoxef The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Latamoxef. Ledipasvir Carboplatin may decrease the excretion rate of Ledipasvir which could result in a higher serum level. Leflunomide The risk or severity of adverse effects can be increased when Carboplatin is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Carboplatin. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin. Lesinurad Carboplatin may decrease the excretion rate of Lesinurad which could result in a higher serum level. Leuprolide Carboplatin may decrease the excretion rate of Leuprolide which could result in a higher serum level. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Levobupivacaine. Levocarnitine Carboplatin may decrease the excretion rate of Levocarnitine which could result in a higher serum level. Levocetirizine Carboplatin may decrease the excretion rate of Levocetirizine which could result in a higher serum level. Levofloxacin Carboplatin may decrease the excretion rate of Levofloxacin which could result in a higher serum level. Levomilnacipran Carboplatin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. Levosalbutamol Carboplatin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. Lidocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Lidocaine. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Carboplatin. Liothyronine Carboplatin may decrease the excretion rate of Liothyronine which could result in a higher serum level. Lipegfilgrastim Carboplatin may increase the myelosuppressive activities of Lipegfilgrastim. Lisinopril Carboplatin may decrease the excretion rate of Lisinopril which could result in a higher serum level. Lithium carbonate Carboplatin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Lithium citrate. Lixisenatide Carboplatin may decrease the excretion rate of Lixisenatide which could result in a higher serum level. Lofexidine Carboplatin may decrease the excretion rate of Lofexidine which could result in a higher serum level. Lomustine The risk or severity of adverse effects can be increased when Carboplatin is combined with Lomustine. Lopinavir The serum concentration of Carboplatin can be increased when it is combined with Lopinavir. Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Carboplatin. Lorazepam Carboplatin may decrease the excretion rate of Lorazepam which could result in a higher serum level. Lorcaserin Carboplatin may decrease the excretion rate of Lorcaserin which could result in a higher serum level. Lornoxicam The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Lornoxicam. Lorpiprazole Carboplatin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. Loxoprofen The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Loxoprofen. Lubiprostone Carboplatin may decrease the excretion rate of Lubiprostone which could result in a higher serum level. Lumiracoxib The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Lumiracoxib. Macitentan Carboplatin may decrease the excretion rate of Macitentan which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Carboplatin. Magnesium carbonate Carboplatin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chloride Carboplatin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium hydroxide Carboplatin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium trisilicate Carboplatin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Carboplatin may decrease the excretion rate of Mangafodipir which could result in a higher serum level. Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Carboplatin. Maprotiline Carboplatin may decrease the excretion rate of Maprotiline which could result in a higher serum level. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Carboplatin. Mecamylamine Carboplatin may decrease the excretion rate of Mecamylamine which could result in a higher serum level. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Carboplatin. Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Carboplatin. Medroxyprogesterone Carboplatin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Carboplatin. Megestrol acetate Carboplatin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. Meloxicam The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Carboplatin is combined with Melphalan. Memantine Carboplatin may decrease the excretion rate of Memantine which could result in a higher serum level. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Carboplatin. Meperidine Carboplatin may decrease the excretion rate of Meperidine which could result in a higher serum level. Mepivacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Carboplatin is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Carboplatin is combined with Mercaptopurine. Meropenem Carboplatin may decrease the excretion rate of Meropenem which could result in a higher serum level. Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Carboplatin. Metamfetamine Carboplatin may decrease the excretion rate of Metamfetamine which could result in a higher serum level. Metamizole The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Metamizole. Metaxalone Carboplatin may decrease the excretion rate of Metaxalone which could result in a higher serum level. Metformin Carboplatin may decrease the excretion rate of Metformin which could result in a higher serum level. Methadone Carboplatin may decrease the excretion rate of Methadone which could result in a higher serum level. Methazolamide Methazolamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Carboplatin. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Carboplatin. Methoxsalen Carboplatin may decrease the excretion rate of Methoxsalen which could result in a higher serum level. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carboplatin. Methyldopa Carboplatin may decrease the excretion rate of Methyldopa which could result in a higher serum level. Methylene blue Carboplatin may decrease the excretion rate of Methylene blue which could result in a higher serum level. Methylnaltrexone Carboplatin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. Methylprednisolone The risk or severity of adverse effects can be increased when Carboplatin is combined with Methylprednisolone. Methyltestosterone Carboplatin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. Meticrane Meticrane may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Metoclopramide Carboplatin may decrease the excretion rate of Metoclopramide which could result in a higher serum level. Metolazone Metolazone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Metoprolol Carboplatin may decrease the excretion rate of Metoprolol which could result in a higher serum level. Metyrapone Carboplatin may decrease the excretion rate of Metyrapone which could result in a higher serum level. Midazolam Carboplatin may decrease the excretion rate of Midazolam which could result in a higher serum level. Migalastat Carboplatin may decrease the excretion rate of Migalastat which could result in a higher serum level. Milnacipran Carboplatin may decrease the excretion rate of Milnacipran which could result in a higher serum level. Milrinone Carboplatin may decrease the excretion rate of Milrinone which could result in a higher serum level. Mirabegron Carboplatin may decrease the excretion rate of Mirabegron which could result in a higher serum level. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Carboplatin. Mitoxantrone The risk or severity of adverse effects can be increased when Carboplatin is combined with Mitoxantrone. Moderna COVID The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Carboplatin. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Carboplatin. Mometasone furoate The risk or severity of adverse effects can be increased when Carboplatin is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Carboplatin is combined with Monomethyl fumarate. Nadolol Carboplatin may decrease the excretion rate of Nadolol which could result in a higher serum level. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Carboplatin. Naldemedine Carboplatin may decrease the excretion rate of Naldemedine which could result in a higher serum level. Nalmefene Carboplatin may decrease the excretion rate of Nalmefene which could result in a higher serum level. Naloxone Carboplatin may decrease the excretion rate of Naloxone which could result in a higher serum level. Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Carboplatin. Natalizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab. Nateglinide Carboplatin may decrease the excretion rate of Nateglinide which could result in a higher serum level. Nedaplatin Carboplatin may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Carboplatin may decrease the excretion rate of Nedocromil which could result in a higher serum level. Nefazodone Carboplatin may decrease the excretion rate of Nefazodone which could result in a higher serum level. Nelarabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Nelarabine. Neomycin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Neomycin. Netilmicin The risk or severity of ototoxicity and nephrotoxicity can be increased when Netilmicin is combined with Carboplatin. Nicorandil Carboplatin may decrease the excretion rate of Nicorandil which could result in a higher serum level. Nifedipine Carboplatin may decrease the excretion rate of Nifedipine which could result in a higher serum level. Nilotinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Nilotinib. Nilutamide Carboplatin may decrease the excretion rate of Nilutamide which could result in a higher serum level. Nimesulide The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Nimesulide. Nisoldipine Carboplatin may decrease the excretion rate of Nisoldipine which could result in a higher serum level. Nitric Oxide Carboplatin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. Nitrofurantoin Carboplatin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nitroprusside Carboplatin may decrease the excretion rate of Nitroprusside which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Carboplatin. Obinutuzumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Carboplatin. Octinoxate Carboplatin may decrease the excretion rate of Octinoxate which could result in a higher serum level. Ofatumumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Ofatumumab. Olaparib The risk or severity of adverse effects can be increased when Carboplatin is combined with Olaparib. Olsalazine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Olsalazine. Opium Carboplatin may decrease the excretion rate of Opium which could result in a higher serum level. Oseltamivir Carboplatin may decrease the excretion rate of Oseltamivir which could result in a higher serum level. Oxacillin Carboplatin may decrease the excretion rate of Oxacillin which could result in a higher serum level. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Carboplatin. Oxaprozin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Oxaprozin. Oxazepam Carboplatin may decrease the excretion rate of Oxazepam which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Oxetacaine. Oxybenzone Carboplatin may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Oxybuprocaine. Oxyphenbutazone The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Oxyphenbutazone. Oxyquinoline Carboplatin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Ozanimod The risk or severity of adverse effects can be increased when Carboplatin is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Carboplatin is combined with Paclitaxel. Palbociclib The risk or severity of adverse effects can be increased when Carboplatin is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Carboplatin. Paliperidone Carboplatin may decrease the excretion rate of Paliperidone which could result in a higher serum level. Palonosetron Carboplatin may decrease the excretion rate of Palonosetron which could result in a higher serum level. Pamidronic acid The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Carboplatin. Panobinostat The risk or severity of adverse effects can be increased when Carboplatin is combined with Panobinostat. Pantoprazole Carboplatin may decrease the excretion rate of Pantoprazole which could result in a higher serum level. Parecoxib The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Parecoxib. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Carboplatin. Paromomycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Paromomycin is combined with Carboplatin. Patent Blue Carboplatin may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pazopanib The risk or severity of adverse effects can be increased when Carboplatin is combined with Pazopanib. Pegaptanib Carboplatin may decrease the excretion rate of Pegaptanib which could result in a higher serum level. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carboplatin. Pegcetacoplan The risk or severity of adverse effects can be increased when Carboplatin is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Carboplatin. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carboplatin. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carboplatin. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Carboplatin is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Carboplatin. Penbutolol Carboplatin may decrease the excretion rate of Penbutolol which could result in a higher serum level. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Carboplatin. Pentaerythritol tetranitrate Carboplatin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Carboplatin. Pentastarch Carboplatin may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Carboplatin may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Carboplatin may decrease the excretion rate of Pentobarbital which could result in a higher serum level. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Carboplatin. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Carboplatin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Carboplatin. Perindopril Carboplatin may decrease the excretion rate of Perindopril which could result in a higher serum level. Permethrin Carboplatin may decrease the excretion rate of Permethrin which could result in a higher serum level. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Carboplatin. Phenazopyridine The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Phenazopyridine. Phenelzine Carboplatin may decrease the excretion rate of Phenelzine which could result in a higher serum level. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Carboplatin. Phenol The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Carboplatin. Phentolamine Carboplatin may decrease the excretion rate of Phentolamine which could result in a higher serum level. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carboplatin. Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Carboplatin. Phenytoin Carboplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. Pholcodine Carboplatin may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Carboplatin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Carboplatin may decrease the excretion rate of Phylloquinone which could result in a higher serum level. Picosulfuric acid Carboplatin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin. Pindolol Carboplatin may decrease the excretion rate of Pindolol which could result in a higher serum level. You Might Also Read Management of Drug Interactions, Types, Guideline Ponatinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Carboplatin is combined with Ponesimod. Potassium Potassium may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Potassium acetate Carboplatin may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Potassium bicarbonate Carboplatin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. Potassium cation Potassium cation may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Potassium chloride Carboplatin may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Potassium citrate Potassium citrate may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Potassium nitrate Carboplatin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. Potassium perchlorate Carboplatin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Potassium sulfate Carboplatin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Pralatrexate The risk or severity of adverse effects can be increased when Carboplatin is combined with Pralatrexate. Pralidoxime Carboplatin may decrease the excretion rate of Pralidoxime which could result in a higher serum level. Pramipexole Carboplatin may decrease the excretion rate of Pramipexole which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Carboplatin. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Carboplatin. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Carboplatin. Pregabalin Carboplatin may decrease the excretion rate of Pregabalin which could result in a higher serum level. Prilocaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Prilocaine. Probenecid Carboplatin may decrease the excretion rate of Probenecid which could result in a higher serum level. Procainamide Carboplatin may decrease the excretion rate of Procainamide which could result in a higher serum level. Procaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Procaine. Procaine benzylpenicillin Carboplatin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Procarbazine The risk or severity of adverse effects can be increased when Carboplatin is combined with Procarbazine. Promethazine Carboplatin may decrease the excretion rate of Promethazine which could result in a higher serum level. Propantheline Carboplatin may decrease the excretion rate of Propantheline which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Proparacaine. Propiverine Carboplatin may decrease the excretion rate of Propiverine which could result in a higher serum level. Propoxycaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Propoxycaine. Propranolol Carboplatin may decrease the excretion rate of Propranolol which could result in a higher serum level. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carboplatin. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Carboplatin. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Carboplatin. Prucalopride Carboplatin may decrease the excretion rate of Prucalopride which could result in a higher serum level. Pyrantel Carboplatin may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Carboplatin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. Pyridoxine Carboplatin may decrease the excretion rate of Pyridoxine which could result in a higher serum level. Pyrithione Carboplatin may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine Carboplatin may decrease the excretion rate of Quetiapine which could result in a higher serum level. Quinethazone Quinethazone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Quinidine Carboplatin may decrease the excretion rate of Quinidine which could result in a higher serum level. Rabeprazole Carboplatin may decrease the excretion rate of Rabeprazole which could result in a higher serum level. Rabies immune globulin, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Carboplatin. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Carboplatin. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Carboplatin. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Carboplatin. Ramelteon Carboplatin may decrease the excretion rate of Ramelteon which could result in a higher serum level. Ranitidine Carboplatin may decrease the excretion rate of Ranitidine which could result in a higher serum level. Ranolazine Carboplatin may decrease the excretion rate of Ranolazine which could result in a higher serum level. Rasagiline Carboplatin may decrease the excretion rate of Rasagiline which could result in a higher serum level. Ravulizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Ravulizumab. Reserpine Carboplatin may decrease the excretion rate of Reserpine which could result in a higher serum level. Resorcinol Carboplatin may decrease the excretion rate of Resorcinol which could result in a higher serum level. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Carboplatin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Carboplatin. Ribavirin Carboplatin may decrease the excretion rate of Ribavirin which could result in a higher serum level. Ribostamycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Ribostamycin is combined with Carboplatin. Rilonacept The risk or severity of adverse effects can be increased when Carboplatin is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Risankizumab. Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Risedronic acid. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Carboplatin. Rivaroxaban Carboplatin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan Carboplatin may decrease the excretion rate of Rizatriptan which could result in a higher serum level. Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Carboplatin. Roflumilast Roflumilast may increase the immunosuppressive activities of Carboplatin. Ropeginterferon The risk or severity of adverse effects can be increased when Carboplatin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Ropivacaine. Rosiglitazone Carboplatin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Carboplatin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Carboplatin. Ruxolitinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Ruxolitinib. Sacubitril Carboplatin may decrease the excretion rate of Sacubitril which could result in a higher serum level. Salbutamol Carboplatin may decrease the excretion rate of Salbutamol which could result in a higher serum level. Salicylamide The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Salicylamide. Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Carboplatin. Salmon calcitonin Carboplatin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level. Salsalate The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Salsalate. Sarilumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Satralizumab. Saxagliptin Carboplatin may decrease the excretion rate of Saxagliptin which could result in a higher serum level. Secobarbital Carboplatin may decrease the excretion rate of Secobarbital which could result in a higher serum level. Secukinumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Secukinumab. Selenious acid Carboplatin may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Carboplatin may decrease the excretion rate of Selenium which could result in a higher serum level. Sibutramine Carboplatin may decrease the excretion rate of Sibutramine which could result in a higher serum level. Siltuximab The risk or severity of adverse effects can be increased when Carboplatin is combined with Siltuximab. Siponimod The risk or severity of adverse effects can be increased when Carboplatin is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carboplatin. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Carboplatin. Sitagliptin Carboplatin may decrease the excretion rate of Sitagliptin which could result in a higher serum level. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Carboplatin. Sodium acetate Carboplatin may decrease the excretion rate of Sodium acetate which could result in a higher serum level. Sodium Carboplatin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Carboplatin. Sodium fluoride Carboplatin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. Sodium sulfate Carboplatin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Sofosbuvir Carboplatin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol Carboplatin may decrease the excretion rate of Solriamfetol which could result in a higher serum level. Sorafenib The risk or severity of death can be increased when Sorafenib is combined with Carboplatin. Sorbitol Carboplatin may decrease the excretion rate of Sorbitol which could result in a higher serum level. Spesolimab The risk or severity of adverse effects can be increased when Carboplatin is combined with Spesolimab. Spironolactone Spironolactone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol Carboplatin may decrease the excretion rate of Stiripentol which could result in a higher serum level. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Carboplatin. Streptomycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Streptomycin is combined with Carboplatin. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Carboplatin. Strontium chloride Carboplatin may decrease the excretion rate of Strontium chloride which could result in a higher serum level. Sucralfate Carboplatin may decrease the excretion rate of Sucralfate which could result in a higher serum level. Sulbactam Carboplatin may decrease the excretion rate of Sulbactam which could result in a higher serum level. Sulfadiazine Carboplatin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Carboplatin. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carboplatin. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Carboplatin. Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Carboplatin. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Carboplatin. Sumatriptan Carboplatin may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The risk or severity of adverse effects can be increased when Carboplatin is combined with Sunitinib. Conjugated Estrogens Carboplatin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. Synthetic Conjugated Carboplatin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Carboplatin. Tadalafil Carboplatin may decrease the excretion rate of Tadalafil which could result in a higher serum level. Tamsulosin Carboplatin may decrease the excretion rate of Tamsulosin which could result in a higher serum level. Tasimelteon Carboplatin may decrease the excretion rate of Tasimelteon which could result in a higher serum level. Technetium Carboplatin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. mebrofenin Carboplatin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. Technetium Carboplatin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. pyrophosphate Carboplatin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Carboplatin is combined with Tedizolid phosphate. Teduglutide Carboplatin may decrease the excretion rate of Teduglutide which could result in a higher serum level. Tegafur Carboplatin may decrease the excretion rate of Tegafur which could result in a higher serum level. Telavancin Carboplatin may decrease the excretion rate of Telavancin which could result in a higher serum level. Temazepam Carboplatin may decrease the excretion rate of Temazepam which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Carboplatin. Temsirolimus The risk or severity of adverse effects can be increased when Carboplatin is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Carboplatin. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Carboplatin. Tenofovir Carboplatin may increase the nephrotoxic activities of Tenofovir alafenamide. Tenofovir disoproxil Carboplatin may increase the nephrotoxic activities of Tenofovir disoproxil. Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Carboplatin. Teprotumumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Teprotumumab. Terbutaline Carboplatin may decrease the excretion rate of Terbutaline which could result in a higher serum level. Teriflunomide The risk or severity of adverse effects can be increased when Carboplatin is combined with Teriflunomide. Testolactone Carboplatin may decrease the excretion rate of Testolactone which could result in a higher serum level. Testosterone Carboplatin may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone cypionate Carboplatin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone enanthate Carboplatin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Testosterone propionate Carboplatin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. Testosterone undecanoate Carboplatin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. Tetracaine The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Tetracaine. Tetracycline Carboplatin may decrease the excretion rate of Tetracycline which could result in a higher serum level. Tetradecyl hydrogen Carboplatin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. Thalidomide The risk or severity of adverse effects can be increased when Carboplatin is combined with Thalidomide. Thiabendazole Carboplatin may decrease the excretion rate of Thiabendazole which could result in a higher serum level. Thiethylperazine Carboplatin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. Thiotepa The risk or severity of adverse effects can be increased when Carboplatin is combined with Thiotepa. Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Tiaprofenic acid. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Carboplatin. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Carboplatin. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Carboplatin. Tiludronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Tiludronic acid. Timolol Carboplatin may decrease the excretion rate of Timolol which could result in a higher serum level. Tinidazole Carboplatin may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Carboplatin. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Carboplatin. Tiopronin Carboplatin may decrease the excretion rate of Tiopronin which could result in a higher serum level. Tiotropium Carboplatin may decrease the excretion rate of Tiotropium which could result in a higher serum level. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Carboplatin. Tixocortol The risk or severity of adverse effects can be increased when Carboplatin is combined with Tixocortol. Tobramycin The risk or severity of ototoxicity and nephrotoxicity can be increased when Tobramycin is combined with Carboplatin. Tocilizumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Tocilizumab. Tocopherol Carboplatin may decrease the excretion rate of Tocopherol which could result in a higher serum level. Tofacitinib Carboplatin may increase the immunosuppressive activities of Tofacitinib. Tolazamide Carboplatin may decrease the excretion rate of Tolazamide which could result in a higher serum level. Tolbutamide Carboplatin may decrease the excretion rate of Tolbutamide which could result in a higher serum level. Tolcapone Carboplatin may decrease the excretion rate of Tolcapone which could result in a higher serum level. Tolfenamic acid The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Tolfenamic acid. Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Carboplatin. Tolterodine Carboplatin may decrease the excretion rate of Tolterodine which could result in a higher serum level. Tolvaptan Tolvaptan may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Topiramate Carboplatin may decrease the excretion rate of Topiramate which could result in a higher serum level. Topotecan The risk or severity of adverse effects can be increased when Carboplatin is combined with Topotecan. Torasemide Torasemide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Carboplatin. Trabectedin The risk or severity of adverse effects can be increased when Carboplatin is combined with Trabectedin. Tramadol Carboplatin may decrease the excretion rate of Tramadol which could result in a higher serum level. Trametinib Carboplatin may decrease the excretion rate of Trametinib which could result in a higher serum level. Trastuzumab Trastuzumab may increase the neutropenic activities of Carboplatin. Trastuzumab The risk or severity of adverse effects can be increased when Carboplatin is combined with Trastuzumab emtansine. Pregnancy and Lactation Pregnancy category D Pregnancy If you are pregnant or think you might be pregnant, or if you are breastfeeding, let your doctor know right away. Carboplatin may harm your developing fetus or breastfeeding baby. If you are a woman of childbearing age, you should use birth control to avoid getting pregnant while you are taking carboplatin. Lactation Most sources consider that mothers receiving antineoplastic therapy should not breastfeed, especially with alkylating agents such as carboplatin.[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. Platinum in milk may increase with repeated courses of chemotherapy and the exact form(s), and toxicity of platinum excreted into breastmilk are also not known. The nursing infant would receive platinum compounds orally rather than intravenously and oral absorption of platinum compounds by infants is not known. It appears that it is not safe to breastfeed after carboplatin chemotherapy, and breastfeeding should probably be discontinued. How should this medicine be used? Carboplatin injection comes as a solution (liquid) to be injected over at least 15 minutes intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once every 4 weeks. Carboplatin is also sometimes used to treat lung, bladder, breast, and endometrial cancer; head and neck cancer; cancer of the cervix and testicles: Wilms’ tumor (a type of kidney cancer that occurs in children); certain types of brain tumors; neuroblastoma (cancer that begins in nerve cells and occurs mainly in children); and retinoblastoma (cancer in the eye). Talk to your doctor about the risks of using this medication for your condition. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving a carboplatin injection, tell your doctor and pharmacist if you are allergic to carboplatin, cisplatin (Platinol), any other medications, or any of the ingredients in carboplatin injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: aminoglycoside antibiotics such as amikacin (Amikin), gentamicin (Garamycin), or tobramycin (Tobi, Nebcin). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with cisplatin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had kidney disease or if you have bleeding problems. tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are receiving carboplatin. If you become pregnant while receiving carboplatin, call your doctor. Carboplatin may harm the fetus. References https://pubchem.ncbi.nlm.nih.gov/compound/Carboplatin https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin https://www.webmd.com/drugs/2/drug-4551/carboplatin-intravenous/details/list-contraindications https://medlineplus.gov/druginfo/meds/a695017.html https://en.wikipedia.org/wiki/Carboplatin https://go.drugbank.com/drugs/DB00958 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Carboplatin [USAN:USP:INN:BAN:JAN] https://chem.nlm.nih.gov/chemidplus/sid/0041575944 DrugBank https://www.drugbank.ca/legal/terms_of_use Carboplatin https://www.drugbank.ca/drugs/DB00958 DTP/NCI https://www.cancer.gov/policies/copyright-reuse carboplatin https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=758182 carboplatin https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=241240 carboplatin https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=201345 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Carboplatin https://comptox.epa.gov/dashboard/DTXSID3046742 European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Diammine[cyclobutane-1,1-dicarboxylato(2-)-O,O’]platinum https://echa.europa.eu/substance-information/-/substanceinfo/100.050.388 Diammine[cyclobutane-1,1-dicarboxylato(2-)-O,O’]platinum https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/57931 Hazardous Substances Data Bank (HSDB) CARBOPLATIN https://pubchem.ncbi.nlm.nih.gov/source/hsdb/6957 ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D016190 Therapeutic Target Database (TTD) Carboplatin http://idrblab.net/ttd/data/drug/details/D0X7HM DailyMed LICENSE https://www.nlm.nih.gov/copyright.html CARBOPLATIN https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CARBOPLATIN Drug-Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking carboplatin https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset livestock LICENSE https://www.nlm.nih.gov/copyright.html Carboplatin https://www.ncbi.nlm.nih.gov/books/n/livertox/Carboplatin/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1282 Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/24262967 NCI Investigational Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse CARBOPLATIN http://dtp.nci.nih.gov/NCI-InvestigationalDrugsCI92/241240%20(1992).txt Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Carboplatin https://www.ncbi.nlm.nih.gov/books/NBK500577/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book LICENSE https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory LICENSE https://www.fda.gov/about-fda/about-website/website-policies#linking CARBOPLATIN https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Carboplatin https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NIST Mass Spectrometry Data Center LICENSE https://www.nist.gov/srd/public-law Carboplatin http://www.nist.gov/srd/nist1a.cfm NLM RxNorm Terminology LICENSE https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html carboplatin https://rxnav.nlm.nih.gov/id/rxnorm/40048 NMRShiftDB https://pubchem.ncbi.nlm.nih.gov/substance/22390115 NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification LICENSE https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ PubChem https://pubchem.ncbi.nlm.nih.gov Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=13061821-63120753 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Carboplatin https://list.essentialmeds.org/medicines/77 Wikipedia Carboplatin https://en.wikipedia.org/wiki/Carboplatin Medical Subject Headings (MeSH) LICENSE https://www.nlm.nih.gov/copyright.html Carboplatin https://www.ncbi.nlm.nih.gov/mesh/68016190 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 Cross-Linking Reagents https://www.ncbi.nlm.nih.gov/mesh/68003432 UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 403720638 https://pubchem.ncbi.nlm.nih.gov/substance/403720638 Show More